Literature DB >> 32231859

Bone recurrence after radical hysterectomy and lymphadenectomy in early-stage cervical cancer.

Caner Çakır1, Dilek Yüksel1, Çiğdem Kılıç1, Mehmet Ünsal1, Rıza Dur1, Gökhan Boyraz1, Alper Karalok1, Özlem Moraloğlu Tekin1, Taner Turan1.   

Abstract

OBJECTIVE: To present the clinical, surgical, and pathologic features of bone recurrence in patients who underwent radical hysterectomy for early-stage uterine cervical cancer.
MATERIALS AND METHODS: Data of 412 patients who underwent type III radical hysterectomy and pelvic ± paraaortic lymphadenectomy for stage 1B-2A epithelial cervical cancer were reviewed. Seven (1.7%) patients with bone recurrence in the first recurrence were included in the study.
RESULTS: The median follow-up of the main cohort (n=412) was 46 (range=1-300) months. In this period, recurrence developed in 53 (12.9%) patients and recurrence was observed in bone in 13.2% (7 of 53) of these recurrences. Time to recurrence ranged from 9 to 45 months. Of the recurrences, five were in the axial skeleton and two were in the appendicular skeleton. Recurrence was observed in lumbar vertebrae in three patients, thoracic vertebrae in one patient, sacral vertebrae in one patient, lumbosacral vertebrae in one patient, and the left femur in two patients. Four patients had multiple recurrence in 3 patients despite isolated bone recurrence. Patients with multiple recurrences died within 6-25 months. All isolated bone recurrences were in the axial skeleton. Complete clinical response with salvage therapy was achieved in two patients with isolated bone recurrence.
CONCLUSION: Complete clinical response and long postoperative survival can be achieved with salvage treatment when bone recurrence is solitary in cervical cancers. ©Copyright 2019 by Turkish Society of Obstetrics and Gynecology | Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

Entities:  

Keywords:  Bone recurrence; salvage therapy; survival; uterine cervical cancer

Year:  2020        PMID: 32231859      PMCID: PMC7090266          DOI: 10.4274/tjod.galenos.2019.26932

Source DB:  PubMed          Journal:  Turk J Obstet Gynecol        ISSN: 2149-9330


  27 in total

1.  Prognostic factors for survival in cervical cancer patients with bone metastasis.

Authors:  T Kanayama; S Mabuchi; K Shimura; T Hisamatsu; F Isohashi; T Hamasaki; T Kimura
Journal:  Eur J Gynaecol Oncol       Date:  2015       Impact factor: 0.196

Review 2.  Management of recurrent cervical cancer: a review of the literature.

Authors:  M Peiretti; I Zapardiel; V Zanagnolo; F Landoni; C P Morrow; A Maggioni
Journal:  Surg Oncol       Date:  2012-01-14       Impact factor: 3.279

3.  Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Authors:  P Bonomi; J A Blessing; F B Stehman; P J DiSaia; L Walton; F J Major
Journal:  J Clin Oncol       Date:  1985-08       Impact factor: 44.544

4.  Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial.

Authors:  J E Kurtz; G Freyer; F Joly; L Gladieff; M C Kaminski; M Fabbro; A Floquet; A C Hardy-Bessard; N Raban; I Ray-Coquard; E Pujade-Lauraine
Journal:  Anticancer Res       Date:  2012-03       Impact factor: 2.480

5.  Site of recurrence of cervical cancer after radical hysterectomy.

Authors:  M J Webb; R E Symmonds
Journal:  Am J Obstet Gynecol       Date:  1980-12-01       Impact factor: 8.661

6.  Distant metastases in squamous-cell carcinoma of the uterine cervix.

Authors:  V Carlson; L Delclos; G H Fletcher
Journal:  Radiology       Date:  1967-05       Impact factor: 11.105

7.  Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix.

Authors:  S Pignata; G Silvestro; E Ferrari; L Selvaggi; F Perrone; A Maffeo; P Frezza; G Di Vagno; G Casella; P Ricchi; G Cormio; C Gallo; F Iodice; F Romeo; R Fiorentino; G Fortuna; S Tramontana
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

8.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

9.  Distant metastases after irradiation alone in carcinoma of the uterine cervix.

Authors:  H Fagundes; C A Perez; P W Grigsby; M A Lockett
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

Review 10.  The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer.

Authors:  Rosa Tambaro; Giovanni Scambia; Massimo Di Maio; Carmela Pisano; Emiddio Barletta; Vincenzo Rosario Iaffaioli; Sandro Pignata
Journal:  Crit Rev Oncol Hematol       Date:  2004-10       Impact factor: 6.312

View more
  1 in total

1.  Clinical Outcomes and Their Prognostic Factors among Cervical Cancer Patients with Bone Recurrence.

Authors:  Thiti Atjimakul; Jitti Hanprasertpong
Journal:  Obstet Gynecol Int       Date:  2022-09-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.